We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




New Point of Care Tests to Help Reduce Overuse of Antibiotics

By LabMedica International staff writers
Posted on 27 Jan 2025

The misuse of antibiotics—such as taking them unnecessarily, for too long, or in incorrect doses—leads to antimicrobial resistance (AMR), making infections harder to treat and increasing the risks of severe illness and death. More...

AMR causes 700,000 global deaths annually, and many people either expect antibiotics from doctors or misuse them by not following prescribed dosages. Doctors face challenges in prescribing antibiotics due to diagnostic uncertainty, patient self-diagnosis, and limited resources. Now, two new tests for bacterial infections could help reduce the overuse of antibiotics for common respiratory illnesses.

Researchers at Deakin University (Victoria, Australia) are leading trials of the two new tests involving a simple finger prick or throat swab that provide immediate results to distinguish between bacterial and viral infections. This can enable more accurate diagnoses and targeted treatments, potentially reducing unnecessary antibiotic prescriptions. In international trials conducted earlier, the finger prick test has already shown promise, while early results from the latest trial indicate a reduction of antibiotic use by up to 30%. This test can help doctors determine if common respiratory infections are bacterial or viral, ensuring antibiotics are only prescribed when necessary.

The second test, a throat swab, allows doctors to quickly identify if a sore throat is caused by Strep A bacteria, a common source of throat infections. Despite Strep A being responsible for only 15 to 20% of sore throats, antibiotics are often overprescribed in 70% of cases. Proper diagnosis and early treatment are critical, especially in children, as Strep A can lead to severe complications like rheumatic heart disease. This throat swab test will optimize antibiotic treatment for Strep A. A feasibility trial conducted in 2024 with 200 patients across five clinics, followed by a pilot trial in 2025 with 400 patients, aims to further assess the test’s effectiveness in reducing antibiotic overuse. Both these trials hold the potential to significantly improve the responsible use of antibiotics.

“This work is trying to improve the capacity of GPs and community pharmacists with point-of-care diagnostic testing services,” said Dr. Sajal Saha, Research Fellow in the Centre for Innovation in Infectious Disease and Immunology Research. “This will help prescribers better understand the severity of infections or confirm bacterial infections for some respiratory infections during patient consultations and prescribe antibiotics accordingly.”

Related Links:
Deakin University


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control
New
Microbiology Laboratory Automation Solution
BD Kiestra™ ReadA+BarcodA
Immunofluorescence Analyzer
IFA System
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Technology

view channel
Image: Graphical Abstract (Wenjie Zhang, Zeyu Luo, Kaijie Liu, et al. Science Bulletin, 2026. doi:10.1016/j.scib.2026.09.016)

Multimodal AI Framework Aims to Guide Cancer Immunotherapy Decisions

Cancer immunotherapy has reshaped oncology, but heterogeneous responses and immune-related toxicities continue to complicate routine decision-making. Standard biomarkers, including programmed death-ligand... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.